On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled for the international Frontiers in Biomagnetic Particles conference in Asheville, North Carolina. Carried out by researchers from Imagion Biosystems, the University of New Mexico, and Sandia National Laboratories, the study demonstrated the use of superparamagnetic relaxometry (SPMR) for specific detection of HER2 positive tumors in mice. The results suggest the utility of SPMR for sensitive and specific detection of cancer, and represent another successful step in the progression of Imagion Biosystems technology. Download the abstract of Dr. Vreeland’s presentation.
Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent
FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and
